This database contains 542 studies, archived under the term: "middle aged"
Click here to filter this large number of results.
A phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii, M. S.,
Walsh, S.,
Little, J. T.,
Behan, K.,
Reynolds, B.,
Ward, C.,
Jin, S.,
Thomas, R.,
Aisen, P. S.
Objective: Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata that may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use for Alzheimer disease (AD).; Methods: We assessed the safety, tolerability, and efficacy of huperzine A in mild to moderate AD in a multicenter trial in which 210 […]
A combination of green tea extract and l-theanine improves memory and attention in subjects with mild cognitive impairment: a double-blind placebo-controlled study
Park, Sang-Ki,
Jung, In-Chul,
Lee, Won Kyung,
Lee, Young Sun,
Park, Hyoung Kook,
Go, Hyo Jin,
Kim, Kiseong,
Lim, Nam Kyoo,
Hong, Jin Tae,
Ly, Sun Yung,
Rho, Seok Seon
A combination of green tea extract and l-theanine (LGNC-07) has been reported to have beneficial effects on cognition in animal studies. In this randomized, double-blind, placebo-controlled study, the effect of LGNC-07 on memory and attention in subjects with mild cognitive impairment (MCI) was investigated. Ninety-one MCI subjects whose Mini Mental State Examination-K (MMSE-K) scores were […]
Donepezil treatment in Alzheimer’s disease patients with and without cerebrovascular lesions: a preliminary report
Na, Hae-Ri,
Kim, SangYun,
Choi, Seong Hye,
Yang, Dong-Won,
Bae, Hee-Joon,
Kim, Jung-Eun,
Park, Mee-Young,
Shim, Yong-Soo,
Kim, Byung-Kun,
Kwon, Jae-Cheol,
Yoo, Bong Goo,
Kim, Byeong-Chae,
Lee, Jung-Seok
Aim: Donepezil has not been evaluated in Korean patients with Alzheimer’s disease (AD) for up to 1 year. The objectives of this study were to evaluate the differential efficacy of donepezil in Korean AD patients with and without concomitant cerebrovascular lesions (CVL).; Methods: This study was a 48-week open-label trial of donepezil in patients with […]
SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
Maher-Edwards, Gareth,
Dixon, Ruth,
Hunter, Jackie,
Gold, Michael,
Hopton, Gillian,
Jacobs, Gemma,
Hunter, Jo,
Williams, Pauline
Objective: To estimate the treatment effects of SB-742457 and donepezil in Alzheimer disease (AD) in a contemporary clinical trial.; Method: Randomized, controlled, parallel-group, exploratory study with a 4-week, single-blind, placebo run-in phase and 24-week, double-blind treatment phase. Primary endpoints were Clinician’s Interview-Based Impression of Change with caregiver input (CIBIC+) and the Alzheimer’s Disease Assessment Scale-cognitive […]
Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation
Lott, Ira T.,
Doran, Eric,
Nguyen, Vinh Q.,
Tournay, Anne,
Head, Elizabeth,
Gillen, Daniel L.
Individuals with Down syndrome over age 40 years are at risk for developing dementia of the Alzheimer type and have evidence for chronic oxidative stress. There is a paucity of treatment trials for dementia in Down syndrome in comparison to Alzheimer disease in the general (non-Down syndrome) population. This 2-year randomized, double-blind, placebo-controlled trial assessed […]
The effects of researcher-composed music at mealtime on agitation in nursing home residents with dementia
Ho, Shu-Yuan,
Lai, Hui-Ling,
Jeng, Shaw-Yeu,
Tang, Chih-Wei,
Sung, Huei-Chuan,
Chen, Pin-Wen
This study examined the effects of music at mealtimes on agitation in 22 nursing home residents with dementia. We used a pretest-posttest research design. We played researcher-composed music to residents at each of two mealtimes daily over a consecutive 4-week period. We observed and recorded agitation 24 hours daily for the 4-week period and the […]
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies
Harrington, C.,
Sawchak, S.,
Chiang, C.,
Davies, J.,
Donovan, C.,
Saunders, A. M.,
Irizarry, M.,
Jeter, B.,
Zvartau-Hind, M.,
van Dyck, C. H.,
Gold, M.
Introduction: Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive therapy to ongoing acetylcholine esterase inhibitor (AChEI) treatment in AD (REFLECT-2, adjunctive to donepezil; REFLECT-3, to any AChEI). An open-label extension study (REFLECT-4) assessed RSG XR long-term safety.; […]